Pre-pregnancy weight in Swedish women and the risk of gestational diabetes and subsequent type 2 diabetes-a population-based cohort study
Abstract
Background: Obesity in young women is increasing. To which extent elevated pre-pregnancy overweight and obesity with and without gestational diabetes increase long-term risk of type 2 diabetes later in life has not been quantified.
Methods: In a Swedish population-based cohort study we used data from the Swedish Medical Birth Registry in 1,153,074 primiparous women included in the registry between Jan 1, 1987 and Dec 31, 2019, with body mass index (BMI) at the first antenatal care visit as a proxy for pre-pregnancy weight to examine risk for gestational diabetes. We then compared women with gestational diabetes (n = 16,870) to age matched comparators (n = 81,862) and calculated hazards for developing type 2 diabetes identified from the National Diabetes registry over a median follow-up of 9 years.
Findings: Among 1,153,074 women, 21,438 (1.9%) were diagnosed with gestational diabetes. Women with pre-pregnancy BMI > 35 kg/m2 had an almost 10-fold risk of gestational diabetes compared to those with low-normal weight. Among women with gestational diabetes, the hazard of type 2 diabetes began to increase already at low- or normal weight, increasing nearly exponentially with rising BMI, while the increase in risk with increasing BMI among women without gestational diabetes was much less marked. No other social/pregnancy related factors improved the prediction of type 2 diabetes.
Interpretation: Gestational diabetes serves as a stress test for developing type 2 diabetes, markedly…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 1,153,074 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.